SCHEMBL4916045

SCHEMBL4916045

O=C(O)c1cc(Nc2c(NCc3cccc(O)c3)c(=O)c2=O)ccc1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.57
NOX4 Q9NPH5 2/20 0.50
RGS12 O14924 1/20 0.50
ALDH1A1 P00352 1/20 0.50
LCK P06239 1/20 0.50
MAPT P10636 1/20 0.50
CAMKK2 Q96RR4 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
KDM4C Q9H3R0 3/20 0.49
HIF1A Q16665 1/20 0.49
PPARA Q07869 1/20 0.46
STING1 Q86WV6 1/20 0.46
MAPKAPK2 P49137 1/20 0.45
GSK3B P49841 3/20 0.45
CLK4 Q9HAZ1 3/20 0.45
MAP4K4 O95819 2/20 0.45
PIM1 P11309 2/20 0.45
CHEK1 O14757 2/20 0.45
DAPK3 O43293 2/20 0.45
ROCK2 O75116 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4905924 0.87 EGFR (0.57) EGFRHIF1AMAPKAPK2GSK3BCLK4
SCHEMBL4919796 0.83 GSK3B (0.48) EGFRALDH1A1MAPTHIF1AMAPKAPK2
SCHEMBL4917069 0.83 EGFR (0.50) EGFRMAPTHIF1AMAPKAPK2GSK3B
SCHEMBL4599292 0.82 HIF1A (0.48) EGFRHIF1AMAPKAPK2GSK3BCLK4
SCHEMBL4906887 0.82 MAPKAPK2 (0.54) EGFRALDH1A1MAPTTDP1HIF1A
SCHEMBL4916629 0.82 EGFR (0.49) EGFRMAPTHIF1AMAPKAPK2GSK3B
SCHEMBL4917914 0.81 EGFR (0.46) EGFRMAPTHIF1AMAPKAPK2GSK3B
SCHEMBL4914009 0.80 EGFR (0.45) EGFRMAPTHIF1AMAPKAPK2GSK3B
SCHEMBL4909304 0.80 EGFR (0.47) EGFRALDH1A1MAPTHIF1AMAPKAPK2
SCHEMBL4913266 0.80 ROCK2 (0.53) EGFRMAPTHIF1AMAPKAPK2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080262096-A1 Squaric Acid Derivatives MERCK PATENT GMBH (DE) 2008-10-23 US claimed
EP-1838662-A1 SQUARIC ACID DERIVATIVES Merck Patent GmbH (DE) 2007-10-03 EP claimed
WO-2006072354-A1 SQUARIC ACID DERIVATIVES MERCK PATENT GMBH (DE) 2006-07-13 WO claimed
US-20080262096-A1 Squaric Acid Derivatives MERCK PATENT GMBH (DE) 2008-10-23 US disclosed
EP-1838662-A1 SQUARIC ACID DERIVATIVES Merck Patent GmbH (DE) 2007-10-03 EP disclosed
WO-2006072354-A1 SQUARIC ACID DERIVATIVES MERCK PATENT GMBH (DE) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262096-A1 Squaric Acid Derivatives GLS, SGK1, PFKL EGFR 2751/4885NOX4 2629/4885RGS12 3016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.